Bullish flow in Pfizer (PFE), with shares up $1.51, or 6.35%, near $25.36. Options volume extremely heavy with 1.04m contracts traded and calls leading puts for a put/call ratio of 0.2, compared to a ...

A new gel-based treatment could change the way diabetic wounds heal. By combining tiny healing messengers called vesicles with a special hydrogel, scientists have created a dressing that restores ...

Pfizer can cover its dividends with free cash flow, but doesn't have a huge cushion. The company faces some risks from pipeline setbacks, patent expirations, and U.S. government policies. Its dividend ...

Pfizer Inc. (NYSE:PFE) is one of the Best Dividend Leaders to Buy Now. The company’s strategy focuses on steadily increasing its dividend, reinvesting in the business with strong financial returns, ...

Pfizer's free cash flow should improve. The drugmaker's lower leverage ratio target gives it greater financial flexibility. New products should cushion the blow from Pfizer's looming patent cliff.